|
|
Prepublished online as a Blood First Edition Paper on February 20, 2003; DOI 10.1182/blood-2002-11-3427.
 Previous Article | Table of Contents | Next Article 
Blood, 1 June 2003, Vol. 101, No. 11, pp. 4437-4445
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
A novel genetic leukocyte adhesion deficiency in subsecond triggering of integrin avidity by endothelial chemokines results in impaired leukocyte arrest on vascular endothelium under shear flow
Ronen Alon,
Memet Aker,
Sara Feigelson,
Maya Sokolovsky-Eisenberg,
Donald E. Staunton,
Guy Cinamon,
Valentin Grabovsky,
Revital Shamri, and
Amos Etzioni
From the Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel; Division of Pediatric Hemato-Oncology, Hadassah Medical Center, Jerusalem, Israel; ICOS, Bothell, WA; and Department of Pediatrics, Meyer Children Hospital, Rambam Medical Center, and the B. Rappaport School of Medicine, Technion, Haifa, Israel.
Leukocyte arrest on vascular endothelium under disruptive shear flow is a multistep process that requires in situ integrin activation on the leukocyte surface by endothelium-displayed chemoattractants, primarily chemokines. A genetic deficiency of leukocyte adhesion to endothelium associated with defective  2 integrin expression or function (LAD-1) has been described. We now report a novel severe genetic disorder in this multistep process associated with functional defects in multiple leukocyte integrins, reflected in recurrent infections, profound leukocytosis, and a bleeding tendency. This syndrome is associated with an impaired ability of neutrophil and lymphocyte 1 and 2 integrins to generate high avidity to their endothelial ligands and arrest cells on vascular endothelium in response to endothelial chemoattractant signals. Patient leukocytes roll normally on endothelial selectins, express intact integrins and G protein–coupled chemokine receptors (GPCR), spread on integrin ligands, and migrate normally along a chemotactic gradient. Activation of 2 integrins in response to GPCR signals and intrinsic soluble ligand binding properties of the very late activation antigen-4 (VLA-4) integrin are also retained in patient leukocytes. Nevertheless, all integrins fail to generate firm adhesion to immobilized ligands in response to in situ GPCR-mediated activation by chemokines or chemoattractants, a result of a primary defect in integrin rearrangement at ligand-bearing contacts. This syndrome is the first example of a human integrin-activation deficiency associated with defective GPCR stimulation of integrin avidity at subsecond contacts, a key step in leukocyte arrest on vascular endothelium under shear flow.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. W. Kuijpers, E. van de Vijver, M. A. J. Weterman, M. de Boer, A. T. J. Tool, T. K. van den Berg, M. Moser, M. E. Jakobs, K. Seeger, O. Sanal, et al.
LAD-1/variant syndrome is caused by mutations in FERMT3
Blood,
May 7, 2009;
113(19):
4740 - 4746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Evans, I. Patzak, L. Svensson, K. De Filippo, K. Jones, A. McDowall, and N. Hogg
Integrins in immunity
J. Cell Sci.,
January 15, 2009;
122(2):
215 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kuijpers, F. Baas, M. Weterman, A. Tool, and D. Roos
Response: Adherence to the LAD variant form
Blood,
December 1, 2007;
110(12):
4129 - 4130.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Pasvolsky, S. W. Feigelson, S. S. Kilic, A. J. Simon, G. Tal-Lapidot, V. Grabovsky, J. R. Crittenden, N. Amariglio, M. Safran, A. M. Graybiel, et al.
A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets
J. Exp. Med.,
July 9, 2007;
204(7):
1571 - 1582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. W. Kuijpers, R. v. Bruggen, N. Kamerbeek, A. T. J. Tool, G. Hicsonmez, A. Gurgey, A. Karow, A. J. Verhoeven, K. Seeger, O. Sanal, et al.
Natural history and early diagnosis of LAD-1/variant syndrome
Blood,
April 15, 2007;
109(8):
3529 - 3537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Garrood, L. Lee, and C. Pitzalis
Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathways
Rheumatology,
March 1, 2006;
45(3):
250 - 260.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Francis, X. Shen, J. B. Young, P. Kaul, and D. J. Lerner
Rho GEF Lsc is required for normal polarization, migration, and adhesion of formyl-peptide-stimulated neutrophils
Blood,
February 15, 2006;
107(4):
1627 - 1635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yonekawa and J. M. Harlan
Targeting leukocyte integrins in human diseases
J. Leukoc. Biol.,
February 1, 2005;
77(2):
129 - 140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Zwartz, A. Chigaev, D. C. Dwyer, T. D. Foutz, B. S. Edwards, and L. A. Sklar
Real-time Analysis of Very Late Antigen-4 Affinity Modulation by Shear
J. Biol. Chem.,
September 10, 2004;
279(37):
38277 - 38286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kinashi, M. Aker, M. Sokolovsky-Eisenberg, V. Grabovsky, C. Tanaka, R. Shamri, S. Feigelson, A. Etzioni, and R. Alon
LAD-III, a leukocyte adhesion deficiency syndrome associated with defective Rap1 activation and impaired stabilization of integrin bonds
Blood,
February 1, 2004;
103(3):
1033 - 1036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hogg, M. Laschinger, K. Giles, and A. McDowall
T-cell integrins: more than just sticking points
J. Cell Sci.,
December 1, 2003;
116(23):
4695 - 4705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
